Syntis Bio Develops Pill Mimicking Gastric Bypass Surgery

Syntis Bio is developing a daily pill that mimics the effects of gastric bypass surgery, aiming to provide a non-surgical weight loss solution. Early animal and human studies suggest the drug is safe and may suppress hunger by redirecting nutrient absorption in the intestines, akin to the surgical procedure's effects. This move comes as the popularity of GLP-1 drugs like Ozempic has surged among weight loss treatments, although many users stop due to side effects or cost. Syntis's research indicates that their pill could lead to weight loss while maintaining lean muscle mass, with promising results in initial trials. The drug's design includes a temporary coating that enhances nutrient absorption and regulates appetite hormones. With an estimated 280,000 gastric bypass surgeries performed in 2022, Syntis aims to offer a viable alternative in the growing obesity treatment market.